Xeris Biopharma Holdings, Inc. Common Stock
$8.20
$0.04 (+0.49%)
$7.93Day Range$8.25
Key Statistics
Market Cap
$1.50B
Shares Outstanding
182.3M
Primary Exchange
XNAS
Currency
USD
Type
CS
IPO Date
Jun 21, 2018
Round Lot
100
Locale
US
Trading Data
Day Open
$8.10
Day High
$8.25
Day Low
$7.93
Volume
4.71M
VWAP
$8.18
Prev Close
$8.16
Transactions
--
Acc. Volume
--
About Xeris Biopharma Holdings, Inc. Common Stock
Xeris Biopharma Holdings Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for people with chronic endocrine and neurological diseases in the United States. It offers Recorlev for the treatment of endogenous hypercortisolemia in patients with Cushing's syndrome; Gvoke for the treatment of severe hypoglycemia; and Keveyis for the treatment of Primary Periodic Paralysis (PPP). Additionally, the company is advancing its Phase 3-ready pipeline product, XP-8121, a once-weekly subcutaneous injection of levothyroxine, which leverages its proprietary technology, XeriSol.
PHARMACEUTICAL PREPARATIONSSIC 2834435 employees1375 WEST FULTON STREET, SUITE 1300, CHICAGO, IL, 60607844-445-5704IPO Jun 21, 2018US / STOCKSActiveWebsite
Identifiers
- CIK
- 0001867096
- Composite FIGI
- BBG012V1MG52
- Share Class FIGI
- BBG012V1MG61
- Ticker Root
- XERS
- SIC Code
- 2834
About Xeris Biopharma Holdings, Inc. Common Stock (XERS) Stock
Xeris Biopharma Holdings, Inc. Common Stock (XERS) closed the 2026-09-18 session at $8.20, up 0.49% versus the previous close (+0.04). The stock opened at $8.10 and traded between $7.93 and $8.25 during that session. Session trading volume was 4.7M shares. The volume-weighted average price (VWAP) is $8.18.
Xeris Biopharma Holdings Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for people with chronic endocrine and neurological diseases in the United States. It offers Recorlev for the treatment of endogenous hypercortisolemia in patients with Cushing's syndrome; Gvoke for the treatment of severe hypoglycemia; and Keveyis for the treatment of Primary Periodic Paralysis (PPP). Additionally, the company is advancing its Phase 3-ready pipeline product, XP-8121, a once-weekly subcutaneous injection of levothyroxine, which leverages its proprietary technology, XeriSol.
Xeris Biopharma Holdings, Inc. Common Stock has a market capitalization of $1.50 billion. The company operates in the PHARMACEUTICAL PREPARATIONS industry classification. XERS is listed on the XNAS exchange. The company employs approximately 435 people. Xeris Biopharma Holdings, Inc. Common Stock is headquartered in CHICAGO, IL. The recorded listing date is 2018-06-21.
On this page you can find market XERS stock price data, interactive price charts with multiple timeframes (1 day to max history), company financials including income statements, balance sheets, and cash flow statements, technical indicators (SMA 50, SMA 200, EMA 20, MACD, RSI), latest news and sentiment analysis, dividend history, stock splits, short interest data, float information, and related stocks.
Explore more: View today's market movers, use the stock screener, or browse all sectors. See more stocks in the PHARMACEUTICAL PREPARATIONS sector.